ELDN Insider Trading - Eledon Pharmaceuticals, Inc.

Utestående aktier	77,187,823 shares
Insideraktier	27 921 493 shares
Insynsägande	36,17 %
Totalt antal insynspersoner	49

Insider Sentiment Score

Insider sentiment score hittar de företag som köps av foretagsinsynspersoner.

Det är resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av insiderackumulation. Poängmodellen använder en kombination av nettoantalet insiders som köpt de föregående 90 dagarna, det totala antalet aktier som köpts i procent av aktiekapitalet och det totala antalet aktier som ägs av insiders. Siffran sträcker sig från 0 till 100, med högre siffror som indikerar en högre nivå av ackumulering för sina kamrater, och 50 är genomsnittet.

Uppdateringsfrekvens: Dagligen

Se Insiders Top Picks, som ger en lista över företag med högsta insiderackumulation.

Se Högst rankade aktier

Office Sentiment Score

Officersentiment Score hittar företag som köps av Corporate Officers.

Per definition Corporate Officers är Corporate Insiders, men till skillnad från vissa av de andra Insiders (10 % aktieägare och styrelseledamöter), arbetar ämbetsmän för företaget dagligen och de använder sina egna pengar när de handlar . (10 % aktieägare och styrelseledamöter är ofta fondförvaltare som förvaltar andras pengar.) Som sådan är insideraffärer som görs av tjänstemän mycket mer betydelsefulla och bör behandlas på lämpligt sätt.

Liksom Insider Sentiment Score är Officer Sentiment Score resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av officersackumulering.

Uppdateringsfrekvens: Dagligen

Se insiderns bästa val, vilket ger en lista över företag med högsta insider sentiment.

Se Högst rankade aktier

Viktiga insidernyckeltal

Denna kort visar hur företaget rankas längs olika insidernyckeltal. Procenttilrankningen visar hur detta företag jämförs med andra företag på USA-marknaden. Högre rankingar indikerar bättre situationer.

Till exempel anses det allmänt att insiderköp är en positiv indikator, så företag med mer insiderköp skulle rankas högre än företag med mindre insiderköp (eller til och med insiderförsäljning).

Nettoantalet insiders som köper (rankning)

0 ( )

2591 out of 10948

Nettoantalet insiders som köper är den totala mängden insiders som säljer minus det totala antalet insiders som säljer under de senaste 90 dagarna. Percentilrankningen visas här (intervall från 0 till 100%).

Procent av flytande köpta av insiders (ranking)

0.000% ( )

2568 out of 10786

Procentandelen av aktier köpta av insiders är det totala antalet aktier som köpts av insiders minus det totala antalet aktier som sålts av insiders under de senaste 90 dagarna, dividerat med det totala antalet aktier och multiplicerat med 100.

Insiderhandelsdiagram

Eledon Pharmaceuticals, Inc. insideraffärer visas i följande diagram. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. I allmänhet är det i allmänhet olagligt för insiders att göra affärer i sina företag baserat på väsentlig, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4.

Insiderlista och lönsamhetsstatistik

Den här tabellen visar listan över kända insiders och genereras automatiskt från anmälningar som avslöjas till SEC. Förutom namnen, den senaste titeln och direktören, tjänstemannen eller ägarbeteckningen på 10 %, tillhandahåller vi de senaste avslöjade innehaven. Dessutom, när det är möjligt tillhandahåller vi insiderns historiska handelsresultat. Det historiska handelsresultatet är ett vägt genomsnitt av resultatet för faktiska köptransaktioner på den öppna marknaden som insidern gjort. För mer information om hur detta beräknas, titta på detta YouTube-webinarium.

See our leaderboard of most profitable insider traders.

Insider	Aktier Ägda	Delad Justerad
Apple Tree Partners Ii Lp Director, 10% Owner - [D] [10%]	4 218 641	4 218 641
Apple Tree Partners II - Annex, L.P. Director, 10% Owner - [D] [10%]	3 568 438	3 568 438
Apple Tree Partners IV, L.P. Director, 10% Owner - [D] [10%]	250 000	250 000
Timothy J Barberich Director - [D]	121 077	121 077
Biotechnology Value Fund Ii Lp -	113 152	220 460
Biotechnology Value Fund L P -	113 152	220 460
Bvf Gp Holdings Llc 10% Owner - [10%]	113 152	220 460
Bvf I Gp Llc -	113 152	220 460
Bvf Ii Gp Llc -	113 152	220 460
Bvf Inc/il 10% Owner - [10%]	113 152	220 460
Bvf Partners L P/il 10% Owner - [10%]	220 460	220 460
BVF Partners OS Ltd. -	113 152	220 460
Biotechnology Value Trading Fund OS LP -	113 152	220 460
Buckley Stephen Jr. Director - [D]	11 000	11 000
Erez Chimovits Director - [D]	3 183 314	3 183 314
Cheryl Cohen Director - [D]	0	0

Insider	Aktier Ägda	Delad Justerad
Flesher Gregory J. Chief Executive Officer, Director - [D] [O]	156 918	156 918
Karen Jean Ferrante	62 000
David-Alexandre C Gros Chief Executive Officer, Director - [D] [O]	9 000	9 000
Seth Loring Harrison Director, 10% Owner - [D] [10%]	7 912 079	7 912 079
Jan Hillson Director - [D]	3 430	3 430
Lee Kalowski Chief Financial Officer - [O]	40 953	40 953
Keith Katkin Director - [D]	8 575	8 575
Kessler David A.	12 000
Allan Kirk Director - [D]	3 430	3 430
Jon Kuwahara See Remarks - [O]	5 974	5 974
Mark N Lampert 10% Owner - [10%]	113 152	220 460
Lifesci Index Partners Llc 10% Owner - [10%]	1 065 867	1 065 867
Gary A Lyons Director - [D]	0	0
June Lee Director - [D]	3 430	3 430
Paul Sean Little CHIEF FINANCIAL OFFICER - [O]	10 000	10 000
Logos Global Management LP 10% Owner - [10%]	224 071	224 071

Insider	Aktier Ägda	Delad Justerad
McBride John S. Director - [D]	3 430	3 430
Jodie Pope Morrison President and CEO, Director - [D] [O]	57 566	57 566
Ag Novartis 10% Owner - [10%]	4 493 458	4 493 458
Bioventures Ltd Novartis 10% Owner - [10%]	4 493 458	4 493 458
Christine Ocampo See Remarks - [O]	23 160	23 160
Walter C Ogier	20 000
OrbiMed Israel BioFund GP Limited Partnership Director, 10% Owner - [D] [10%]	73 650	73 650
OrbiMed Israel GP Ltd. 10% Owner - [10%]	73 650	73 650
Steven Perrin President, Director - [D] [O]	1 000	1 000
Gerald E Quirk	62 000
Robinson James A. Jr. Director - [D]	3 430	3 430
Muneer A Satter 10% Owner - [10%]	1 771 688	1 771 688
Smith Bryan E.	120 000
Turkel Catherine C. President - [O]	88 662	88 662
Martin D Williams 10% Owner - [10%]	337 700	337 700
Paul Yook 10% Owner - [10%]	1 065 867	1 065 867
Yanchik Joseph A., III Director - [D]	51 092	51 092

Report errors via our new Insider Auditing Tool

Track Records av insiderköp - Kortsiktig vinstanalys

I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i ELDN / Eledon Pharmaceuticals, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .

Tabellen nedan visar de senaste köpen på öppna marknaden som inte var en del av en automatisk handelsplan.

Handelsdatum	Insider	Rapporterade aktier	Rapporterat pris	Justerade aktier	Justerat pris	Kostnadsbasis	Dagar til Max	Pris vid Max
2024-05-09	BVF PARTNERS L P/IL	1 031 385		1 031 385			176	5.3000
2024-05-09	BVF PARTNERS L P/IL	821 121		821 121
2024-05-09	BVF PARTNERS L P/IL	75 431		75 431
2023-05-05	BVF PARTNERS L P/IL	1 055 445		1 055 445
2023-05-05	BVF PARTNERS L P/IL	837 146		837 146
2023-05-05	BVF PARTNERS L P/IL	86 341		86 341
2022-11-23	Perrin Steven	1 000	2,5969	1 000	2,5969	2 597
2021-12-20	Gros David-Alexandre C	2 000	4,4800	2 000	4,4800	8 960
2021-08-17	Gros David-Alexandre C	4 000	6,2100	4 000	6,2100	24 840

Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.

ELDN / Eledon Pharmaceuticals, Inc. Insider Trades

Track Records av insiderförsäljning - Kortsiktig förlustanalys

Tabellen nedan visar de senaste försäljningarna på öppna marknaden som inte var en del av en automatisk handelsplan.

Handelsdatum	Insider	Rapporterade aktier	Rapporterat pris	Justerade aktier	Justerat pris	Kostnadsbasis	Dagar til Min	Pris vid Min	Maximal förlust undvikits ($)	Maximal förlust undvikits ($)
2020-12-02	OrbiMed Israel GP Ltd.	103 200	21,6000	103 200	21,6000	2 229 120	22	13.8100	−803 928	−36,06
2020-10-30	Logos Global Management LP	27	27,0200	27	27,0200	730
2020-10-30	Logos Global Management LP	12 942	26,6442	12 942	26,6442	344 829
2019-05-21	TURKEL CATHERINE C.	1 914	1,9114	106	34,4052	3 658
2019-05-21	FLESHER GREGORY J.	2 937	1,9114	163	34,4052	5 614

Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.

Transaktionshistorik

Klicka på länkikonen för att se hela transaktionshistoriken. Transaktioner som rapporteras som en del av en automatisk handelsplan 10b5-1 kommer att ha ett X i kolumnen markerad 10b-5.

Fil datum	Handel datum	Schema	Insider	Ticker	Värdepappertitel	Kod	Direkta	Utövningspris	Enhet pris	Enheter ändrad	Värde ändrad (1K)	Kvarvarande Optioner	Kvarvarande Aktier
2026-01-16	2026-01-10	4	Robinson James A. Jr.	ELDN	Common Stock	M - Exercise	D			3 430			3 430
2026-01-16	2026-01-10	4	Lee June	ELDN	Common Stock	M - Exercise	D			3 430			3 430
2026-01-16	2026-01-10	4	Katkin Keith	ELDN	Common Stock	M - Exercise	D			8 575			8 575
2026-01-16	2026-01-10	4	Kirk Allan	ELDN	Common Stock	M - Exercise	D			3 430			3 430
2026-01-16	2026-01-10	4	Hillson Jan	ELDN	Common Stock	M - Exercise	D			3 430			3 430
2026-01-16	2026-01-10	4	McBride John S.	ELDN	Common Stock	M - Exercise	D			3 430			3 430
2024-05-13	2024-05-09	4	BVF PARTNERS L P/IL	ELDN	Common Stock, $0.001 par value	P - Purchase	D			75 431			220 460
2024-05-13	2024-05-09	4	BVF PARTNERS L P/IL	ELDN	Common Stock, $0.001 par value	P - Purchase	D			821 121			2 633 679
2024-05-13	2024-05-09	4	BVF PARTNERS L P/IL	ELDN	Common Stock, $0.001 par value	P - Purchase	D			1 031 385			3 361 803
2023-05-09	2023-05-05	4	BVF PARTNERS L P/IL	ELDN	Common Stock, $0.001 par value	P - Purchase	D			86 341			145 029
2023-05-09	2023-05-05	4	BVF PARTNERS L P/IL	ELDN	Common Stock, $0.001 par value	P - Purchase	D			837 146			1 812 558
2023-05-09	2023-05-05	4	BVF PARTNERS L P/IL	ELDN	Common Stock, $0.001 par value	P - Purchase	D			1 055 445			2 330 418
2022-11-23	2022-11-23	4	Perrin Steven	ELDN	Common Stock	P - Purchase	D		2,5969	1 000	3		1 000
2022-02-02	2022-02-01	4	Gros David-Alexandre C	ELDN	Stock Option (right to buy)	A - Award	D	3,97		108 000		108 000
2022-02-02	2022-02-01	4	Smith Bryan E.	ELDN	Stock Option (right to buy)	A - Award	D	3,97		120 000		120 000
2022-02-02	2022-02-01	4	Ogier Walter C	ELDN	Stock Option (right to buy)	A - Award	D	3,97		20 000		20 000
2022-02-02	2022-02-01	4	Perrin Steven	ELDN	Stock Option (right to buy)	A - Award	D	3,97		155 000		155 000
2022-02-02	2022-02-01	4	McBride John S.	ELDN	Stock Option (right to buy)	A - Award	D	3,97		20 000		20 000
2022-02-02	2022-02-01	4	LYONS GARY A	ELDN	Stock Option (right to buy)	A - Award	D	3,97		20 000		20 000
2022-02-02	2022-02-01	4	Lee June	ELDN	Stock Option (right to buy)	A - Award	D	3,97		20 000		20 000
2022-02-02	2022-02-01	4	Hillson Jan	ELDN	Stock Option (right to buy)	A - Award	D	3,97		20 000		20 000
2022-02-02	2022-02-01	4	Katkin Keith	ELDN	Stock Option (right to buy)	A - Award	D	3,97		20 000		20 000
2022-02-02	2022-02-01	4	Little Paul Sean	ELDN	Stock Option (right to buy)	A - Award	D	3,97		155 000		155 000
2022-01-31		3	LAMPERT MARK N	ELDN	Common Stock, $0.001 par value		D						975 412
2022-01-31		3	LAMPERT MARK N	ELDN	Common Stock, $0.001 par value		D						1 274 973
2022-01-31		3	LAMPERT MARK N	ELDN	Common Stock, $0.001 par value		D						58 688
2021-12-21	2021-12-20	4	Gros David-Alexandre C	ELDN	Common Stock	P - Purchase	D		4,4800	2 000	9		9 000
2021-08-19	2021-08-17	4	Gros David-Alexandre C	ELDN	Common Stock	P - Purchase	D		6,2100	4 000	25		7 000
2021-06-14	2021-06-11	4	Little Paul Sean	ELDN	Common Stock	P - Purchase	D		8,8700	10 000	89		10 000
2021-06-10	2021-06-09	4	Gros David-Alexandre C	ELDN	Common Stock	P - Purchase	D		8,0100	3 000	24		3 000
2021-05-04	2021-05-03	4	Smith Bryan E.	ELDN	Stock Option (Right to Buy)	A - Award	D	9,91		158 500		158 500
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Series X1 Convertible Preferred Stock	C - Conversion	D			−1 757		6 758
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Series X1 Convertible Preferred Stock	C - Conversion	D			−9 169		39 693
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Series X1 Convertible Preferred Stock	C - Conversion	D			−11 776		52 145
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Series X Convertible Preferred	C - Conversion	D			−35		0
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Series X Convertible Preferred	C - Conversion	D			−203		0
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Series X Convertible Preferred	C - Conversion	D			−273		0
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Common Stock, $0.001 par value	C - Conversion	D			97 615			113 152
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Common Stock, $0.001 par value	C - Conversion	D			1 944			15 537
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Common Stock, $0.001 par value	C - Conversion	D			509 410			598 624
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Common Stock, $0.001 par value	C - Conversion	D			11 278			89 214
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Common Stock, $0.001 par value	C - Conversion	D			654 215			771 780
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Common Stock, $0.001 par value	C - Conversion	D			15 166			117 565
2020-12-04	2020-12-02	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Common Stock	S - Sale	I		21,6000	−103 200	−2 229		73 650
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		25,5507	9 098	232		224 071
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		26,1740	15 000	393		214 973
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	S - Sale	I		27,0200	−27	−1		199 973
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		25,8790	12 942	335		200 000
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	S - Sale	I		26,6442	−12 942	−345		187 058
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		26,4824	15 000	397		200 000
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		25,9730	4 000	104		185 000
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		24,5299	31 000	760		181 000
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		24,0325	5 000	120		150 000
2020-11-06		3	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock		I						145 000
2020-10-05		3	LAMPERT MARK N	NVUS	Common Stock		D						77 936
2020-10-05		3	LAMPERT MARK N	NVUS	Common Stock		D						102 400
2020-10-05		3	LAMPERT MARK N	NVUS	Common Stock		D						13 595
2020-09-15	2020-09-11	4	LYONS GARY A	NVUS	Stock Option (Right to Buy)	A - Award	D	500,00		1 167		1 167
2020-09-15	2020-09-11	4	McBride John S.	NVUS	Stock Option (Right to Buy)	A - Award	D	500,00		1 167		1 167
2020-09-15	2020-09-11	4	Kuwahara Jon	NVUS	Stock Option (Right to Buy)	A - Award	D	500,00		2 145		2 145
2020-09-15	2020-09-11	4	Katkin Keith	NVUS	Stock Option (Right to Buy)	A - Award	D	500,00		5 907		5 907
2020-09-15	2020-09-11	4	Gros David-Alexandre C	NVUS	Stock Option (Right to Buy)	A - Award	D	500,00		18 278		18 278
2020-03-20	2020-03-19	4	Kuwahara Jon	NVUS	Stock Option (Right to Buy)	A - Award	D	0,26		50 000		50 000
2020-03-20	2020-03-19	4	TURKEL CATHERINE C.	NVUS	Stock Option (Right to Buy)	A - Award	D	0,26		100 000		100 000
2020-03-20	2020-03-19	4	FLESHER GREGORY J.	NVUS	Stock Option (Right to Buy)	A - Award	D	0,26		200 000		200 000
2020-02-25	2020-01-14	4	Chimovits Erez See Footnotes	NVUS	Warrants to Purchase Common Stock	S - Sale	I		0,2000	646 204	129	0
2020-02-25	2020-01-14	4	Chimovits Erez See Footnotes	NVUS	Warrants to Purchase Common Stock	S - Sale	I		0,2000	646 204	129	0
2020-02-25	2020-01-14	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Warrants to Purchase Common Stock	S - Sale	I		0,2000	646 204	129
2020-02-25	2020-01-14	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Warrants to Purchase Common Stock	S - Sale	I		0,2000	646 204	129
2019-09-30	2019-09-26	4	FLESHER GREGORY J.	NVUS	Stock Option (Right to Buy)	A - Award	D	0,67		100 000		100 000
2019-09-30	2019-09-26	4	TURKEL CATHERINE C.	NVUS	Stock Option (Right to Buy)	A - Award	D	0,67		75 000		75 000
2019-09-30	2019-09-26	4	Kuwahara Jon	NVUS	Stock Option (Right to Buy)	A - Award	D	0,67		60 000		60 000
2019-07-15	2019-07-11	4	Chimovits Erez	NVUS	Stock Option (Right to Buy)	A - Award	D	0,88		20 000		20 000
2019-07-15	2019-07-11	4	Katkin Keith	NVUS	Stock Option (Right to Buy)	A - Award	D	0,88		20 000		20 000
2019-07-15	2019-07-11	4	McBride John S.	NVUS	Stock Option (Right to Buy)	A - Award	D	0,88		20 000		20 000
2019-07-15	2019-07-11	4	Cohen Cheryl	NVUS	Stock Option (Right to Buy)	A - Award	D	0,88		20 000		20 000
2019-07-15	2019-07-11	4	LYONS GARY A	NVUS	Stock Option (Right to Buy)	A - Award	D	0,88		20 000		20 000
2019-05-22	2019-05-21	4	FLESHER GREGORY J.	NVUS	Common Stock	S - Sale	D		1,9114	−2 937	−6		156 918
2019-05-22	2019-05-20	4	FLESHER GREGORY J.	NVUS	Common Stock	S - Sale	D		1,9616	−11 701	−23		159 855
2019-05-22	2019-05-21	4	Kuwahara Jon	NVUS	Common Stock	S - Sale	D		1,9114	−1 058	−2		5 974
2019-05-22	2019-05-20	4	Kuwahara Jon	NVUS	Common Stock	S - Sale	D		1,9616	−4 218	−8		7 032
2019-05-22	2019-05-21	4	TURKEL CATHERINE C.	NVUS	Common Stock	S - Sale	D		1,9114	−1 914	−4		88 662
2019-05-22	2019-05-20	4	TURKEL CATHERINE C.	NVUS	Common Stock	S - Sale	D		1,9616	−7 623	−15		90 576
2019-05-06	2019-05-02	4	Chimovits Erez See Footnotes	NVUS	Warrants to Purchase Common Stock	P - Purchase	I			646 204		646 204
2019-05-06	2019-05-02	4	Chimovits Erez See Footnotes	NVUS	Warrants to Purchase Common Stock	P - Purchase	I			646 204		646 204
2019-05-06	2019-05-02	4	Chimovits Erez	NVUS	Common Stock	P - Purchase	I		3,1000	646 204	2 003		3 183 314
2019-05-06	2019-05-02	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Warrants to Purchase Common Stock	P - Purchase	I			646 204		646 204
2019-05-06	2019-05-02	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Warrants to Purchase Common Stock	P - Purchase	I			646 204		646 204
2019-05-06	2019-05-02	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Common Stock	P - Purchase	I		3,1000	646 204	2 003		3 183 314
2019-05-02	2019-04-30	4	LIFESCI INDEX PARTNERS LLC	NVUS	Common Stock, par value $0.01 per share	S - Sale	I		2,7000	−200	−1		1 065 867
2019-03-18	2019-03-14	4	Kuwahara Jon	NVUS	Stock Option (Right to Buy)	A - Award	D	3,72		25 000		25 000
2019-03-18	2019-03-14	4	FLESHER GREGORY J.	NVUS	Stock Option (Right to Buy)	A - Award	D	3,72		90 000		90 000
2019-03-18	2019-03-14	4	FLESHER GREGORY J.	NVUS	Common Stock	A - Award	D			25 000			171 556
2019-03-18	2019-03-14	4	TURKEL CATHERINE C.	NVUS	Stock Option (Right to Buy)	A - Award	D	3,72		50 000		50 000
2019-03-18	2019-03-14	4	TURKEL CATHERINE C.	NVUS	Common Stock	A - Award	D			20 000			98 199
2018-09-13	2018-09-12	4	TURKEL CATHERINE C.	NVUS	Common Stock	P - Purchase	D		5,0190	16 632	83		78 199
2018-09-13	2018-09-11	4	TURKEL CATHERINE C.	NVUS	Common Stock	P - Purchase	D		4,5560	17 048	78		61 567
2018-09-07	2018-09-05	4	TURKEL CATHERINE C. By Spouse's IRA	NVUS	Common Stock	P - Purchase	I		3,9660	805	3		805
2018-06-14	2018-06-13	4	McBride John S.	NVUS	Stock Option (Right to Buy)	A - Award	D	6,18		9 100		9 100
2018-06-14	2018-06-13	4	Katkin Keith	NVUS	Stock Option (Right to Buy)	A - Award	D	6,18		9 100		9 100
2018-06-14	2018-06-13	4	LYONS GARY A	NVUS	Stock Option (Right to Buy)	A - Award	D	6,18		9 100		9 100
2018-06-14	2018-06-13	4	Cohen Cheryl	NVUS	Stock Option (Right to Buy)	A - Award	D	6,18		9 100		9 100
2018-03-20		3	LIFESCI INDEX PARTNERS LLC	NVUS	Common Stock, $.001 par value		I						2 132 134
2018-03-20		3	LIFESCI INDEX PARTNERS LLC	NVUS	Common Stock, $.001 par value		I						2 132 134
2018-03-20		3	LIFESCI INDEX PARTNERS LLC	NVUS	Common Stock, $.001 par value		I						2 132 134
2018-03-20		3	LIFESCI INDEX PARTNERS LLC	NVUS	Common Stock, $.001 par value		I						2 132 134
2018-03-15	2018-03-13	4	TURKEL CATHERINE C.	NVUS	Stock Option (Right to Buy)	A - Award	D	4,83		24 000		24 000
2018-03-15	2018-03-13	4	TURKEL CATHERINE C.	NVUS	Common Stock	A - Award	D			20 000			44 519
2018-03-15	2018-03-13	4	FLESHER GREGORY J.	NVUS	Stock Option (Right to Buy)	A - Award	D	4,83		56 500		56 500
2018-03-15	2018-03-13	4	FLESHER GREGORY J.	NVUS	Common Stock	A - Award	D			30 700			146 556
2018-03-15	2018-03-13	4	Kuwahara Jon	NVUS	Stock Option (Right to Buy)	A - Award	D	4,83		12 000		12 000
2018-03-15	2018-03-13	4	Kuwahara Jon	NVUS	Common Stock	A - Award	D			11 250			11 250
2017-11-06	2017-11-06	4	TURKEL CATHERINE C.	NVUS	Stock Option (Right to Buy)	A - Award	D	4,21		50 000		50 000
2017-07-10	2017-07-10	4	Kuwahara Jon	NVUS	Stock Option (Right to Buy)	A - Award	D	5,61		35 000		35 000
2017-07-05	2017-06-30	4	Katkin Keith	NVUS	Stock Option (Right to Buy)	A - Award	D	5,85		36 000		36 000
2017-07-05	2017-06-30	4	Morrison Jodie Pope	NVUS	Stock Option (Right to Buy)	A - Award	D	5,85		18 000		18 000
2017-07-05	2017-06-30	4	Cohen Cheryl	NVUS	Stock Option (Right to Buy)	A - Award	D	5,85		18 000		18 000
2017-07-05	2017-06-30	4	McBride John S.	NVUS	Stock Option (Right to Buy)	A - Award	D	5,85		18 000		18 000
2017-07-05	2017-06-30	4	LYONS GARY A	NVUS	Stock Option (Right to Buy)	A - Award	D	5,85		18 000		18 000
2017-05-26	2017-05-24	4	OCAMPO CHRISTINE	NVUS	Stock Option (Right to Buy)	A - Award	D	5,50		52 500		52 500
2017-05-26	2017-05-24	4	TURKEL CATHERINE C.	NVUS	Stock Option (Right to Buy)	A - Award	D	5,50		52 500		52 500
2017-05-26	2017-05-24	4	FLESHER GREGORY J.	NVUS	Stock Option (Right to Buy)	A - Award	D	5,50		250 000		250 000
2017-05-11		3	LYONS GARY A	NVUS	No Securities Owned		D						0
2017-05-11		3	FLESHER GREGORY J.	NVUS	Common Stock		D						113 794
2017-05-11		3	FLESHER GREGORY J.	NVUS	Common Stock		D						113 794
2017-05-11		3	TURKEL CATHERINE C.	NVUS	Common Stock		D						26 816
2017-05-11		3	TURKEL CATHERINE C.	NVUS	Common Stock		D						26 816
2017-05-11		3	Katkin Keith	NVUS	Common Stock		D						24 238
2017-05-11		3	Katkin Keith	NVUS	Common Stock		D						24 238
2017-05-11		3	OCAMPO CHRISTINE	NVUS	Common Stock		D						23 160
2017-05-11		3	OCAMPO CHRISTINE	NVUS	Common Stock		D						23 160
2017-05-11		3	Chimovits Erez By OrbiMed Israel GP Ltd.	NVUS	Common Stock		I						5 074 220
2017-05-11		3	Chimovits Erez By OrbiMed Israel GP Ltd.	NVUS	Common Stock		I						5 074 220
2017-05-11	2017-05-10	4	FLESHER GREGORY J.	NVUS	Common Stock	P - Purchase	D		9,9900	58 959	589		115 856
2017-05-11	2017-05-10	4	OCAMPO CHRISTINE	NVUS	Common Stock	P - Purchase	D		9,9900	10 010	100		21 590
2017-05-11	2017-05-10	4	TURKEL CATHERINE C.	NVUS	Common Stock	P - Purchase	D		9,9900	11 111	111		24 519
2017-05-11	2017-05-09	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Common Stock	A - Award	I			2 537 110			2 537 110
2016-06-16	2016-06-15	4	BARBERICH TIMOTHY J	TKAI	Stock Option (right to buy)	A - Award	D	6,29		12 000		12 000
2016-06-16	2016-06-15	4	Harrison Seth Loring	TKAI	Stock Option (right to buy)	A - Award	D	6,29		12 000		12 000
2016-06-16	2016-06-16	4	Cohen Cheryl	TKAI	Stock Option (right to buy)	A - Award	D	6,29		12 000		12 000
2016-06-16	2016-06-15	4	Buckley Stephen Jr.	TKAI	Stock Option (right to buy)	A - Award	D	6,29		12 000		12 000
2016-06-16	2016-06-15	4	Yanchik Joseph A., III	TKAI	Stock Option (right to buy)	A - Award	D	6,29		12 000		12 000
2016-06-16	2016-06-15	4	Kessler David A.	TKAI	Stock Option (right to buy)	A - Award	D	6,29		12 000		12 000
2016-03-15	2016-03-15	4	Buckley Stephen Jr.	TKAI	Common Stock	P - Purchase	D		5,7400	8 000	46		11 000
2016-01-08	2016-01-08	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	1,37		−20 000		37 878
2016-01-08	2016-01-08	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	0,63		−8 015		0
2016-01-08	2016-01-08	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		1,3700	20 000	27		57 566
2016-01-08	2016-01-08	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		0,6300	8 015	5		37 566
2015-12-17	2015-12-15	4	Ferrante Karen Jean	TKAI	Stock Option (right to buy)	A - Award	D	9,65		62 000		62 000
2015-12-17	2015-12-15	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	A - Award	D	9,65		189 000		189 000
2015-12-17	2015-12-15	4	Kalowski Lee	TKAI	Stock Option (right to buy)	A - Award	D	9,65		62 000		62 000
2015-12-17	2015-12-15	4	McBride John S.	TKAI	Stock Option (right to buy)	A - Award	D	9,65		62 000		62 000
2015-12-17	2015-12-15	4	Quirk Gerald E	TKAI	Stock Option (right to buy)	A - Award	D	9,65		62 000		62 000
2015-11-12	2015-11-11	4	Buckley Stephen Jr.	TKAI	Common Stock	P - Purchase	D		11,2500	3 000	34		3 000
2015-09-22	2015-09-21	4	McBride John S.	TKAI	Stock Option (right to buy)	M - Exercise	D	4,19		−13 500		186 678
2015-09-22	2015-09-21	4	McBride John S.	TKAI	Common Stock	S - Sale	D		14,0100	−13 500	−189		0
2015-09-22	2015-09-21	4	McBride John S.	TKAI	Common Stock	M - Exercise	D		4,1900	13 500	57		13 500
2015-09-08	2015-09-08	4	Kalowski Lee	TKAI	Common Stock	S - Sale	D		13,1300	−4 668	−61		40 953
2015-09-04	2015-09-02	4	Kalowski Lee	TKAI	Common Stock	S - Sale	D		12,9600	−2 158	−28		45 621
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	1,37		−3 000		57 878
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	0,63		−7 000		8 015
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	1,58		−564		312 736
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		1,3700	3 000	4		29 551
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		0,6300	7 000	4		26 551
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Common Stock	S - Sale	D		13,7000	−564	−8		19 551
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		1,5800	564	1		20 115
2015-07-30	2015-07-28	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	1,58		−12 000		313 300
2015-07-30	2015-07-28	4	Morrison Jodie Pope	TKAI	Common Stock	S - Sale	D		13,7000	−12 000	−164		19 551
2015-07-30	2015-07-28	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		1,5800	12 000	19		31 551
2015-07-24	2015-07-22	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	0,63		−7 426		15 015
2015-07-24	2015-07-22	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	2,31		−2 574		0
2015-07-24	2015-07-22	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		0,6300	7 426	5		19 551
2015-07-24	2015-07-22	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		2,3100	2 574	6		12 125
2015-07-17	2015-07-15	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14,2580	−3 566	−51		4 493 458
2015-07-15	2015-07-14	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14,4100	−27 861	−401		4 497 024
2015-07-15	2015-07-13	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14,2020	−20 611	−293		4 524 885
2015-06-30	2015-06-29	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	1,58		−8 000		325 300
2015-06-30	2015-06-29	4	Morrison Jodie Pope	TKAI	Common Stock	S - Sale	D		13,7000	−8 000	−110		9 551
2015-06-30	2015-06-29	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		1,5800	8 000	13		17 551
2015-06-30	2015-06-26	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	1,58		−8 000		333 300
2015-06-30	2015-06-26	4	Morrison Jodie Pope	TKAI	Common Stock	S - Sale	D		13,8300	−8 000	−111		9 551
2015-06-30	2015-06-26	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		1,5800	8 000	13		17 551
2015-06-24	2015-06-24	4	McBride John S.	TKAI	Stock Option (right to buy)	M - Exercise	D	4,19		−300		200 178
2015-06-24	2015-06-24	4	McBride John S.	TKAI	Common Stock	S - Sale	D		14,2000	−300	−4		0
2015-06-24	2015-06-24	4	McBride John S.	TKAI	Common Stock	M - Exercise	D		4,1900	300	1		300
2015-06-24	2015-06-23	4	McBride John S.	TKAI	Stock Option (right to buy)	M - Exercise	D	4,19		−6 700		200 478
2015-06-24	2015-06-23	4	McBride John S.	TKAI	Common Stock	S - Sale	D		14,0000	−6 700	−94		0
2015-06-24	2015-06-23	4	McBride John S.	TKAI	Common Stock	M - Exercise	D		4,1900	6 700	28		6 700
2015-06-24	2015-06-22	4	McBride John S.	TKAI	Stock Option (right to buy)	M - Exercise	D	4,19		−2 000		207 178
2015-06-24	2015-06-22	4	McBride John S.	TKAI	Common Stock	S - Sale	D		14,0200	−2 000	−28		0
2015-06-24	2015-06-22	4	McBride John S.	TKAI	Common Stock	M - Exercise	D		4,1900	2 000	8		2 000
2015-06-19	2015-06-17	4	BARBERICH TIMOTHY J	TKAI	Stock Option (right to buy)	A - Award	D	14,04		12 000		12 000
2015-06-19	2015-06-17	4	Harrison Seth Loring	TKAI	Stock Option (right to buy)	A - Award	D	14,04		12 000		12 000
2015-06-19	2015-06-17	4	Buckley Stephen Jr.	TKAI	Stock Option (right to buy)	A - Award	D	14,04		12 000		12 000
2015-06-19	2015-06-17	4	Yanchik Joseph A., III	TKAI	Stock Option (right to buy)	A - Award	D	14,04		12 000		12 000
2015-06-19	2015-06-17	4	Kessler David A.	TKAI	Stock Option (right to buy)	A - Award	D	14,04		12 000		12 000
2015-06-18	2015-06-16	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14,2700	−1 120	−16		4 545 496
2015-06-16	2015-06-12	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14,2000	−5 919	−84		4 561 393
2015-06-16	2014-06-15	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14,2000	−14 777	−210		4 546 616
2015-06-12	2015-06-11	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14,2000	−27 875	−396		4 567 312
2015-05-28	2015-05-26	4	Quirk Gerald E	TKAI	Stock Option (right to buy)	A - Award	D	10,81		214 605		214 605
2015-04-20	2015-04-16	4	Kalowski Lee	TKAI	Common Stock	S - Sale	D		13,0000	−4 567	−59		47 779
2015-04-13		3	Cohen Cheryl	TKAI	No securities are beneficially owned		D						0
2015-04-13	2015-04-09	4	Cohen Cheryl	TKAI	Stock Option (right to buy)	A - Award	D	11,08		25 000		25 000
2015-04-06	2015-04-02	4	Kalowski Lee	TKAI	Common Stock	S - Sale	D		11,4500	−2 258	−26		52 346
2015-03-20	2015-03-19	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14,5000	−46 141	−669		4 595 187
2015-03-20	2015-03-18	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14,5000	−3 000	−44		4 641 328
2015-01-12		3	Buckley Stephen Jr.	TKAI	No securities are beneficially owned		D						0
2015-01-12	2015-01-08	4	Buckley Stephen Jr.	TKAI	Stock Option (right to buy)	A - Award	D	14,49		25 000		25 000
2014-10-17	2014-10-15	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	A - Award	D	13,25		134 134		134 134
2014-10-17	2014-10-15	4	McBride John S.	TKAI	Stock Option (right to buy)	A - Award	D	13,25		50 671		50 671
2014-09-24	2014-09-22	4	Satter Muneer A See footnote.	TKAI	Series E Preferred Stock	C - Conversion	I			−8 013 003		0
2014-09-24	2014-09-22	4	Satter Muneer A See footnote.	TKAI	Series D-3 Preferred Stock	C - Conversion	I			−3 931 085		0
2014-09-24	2014-09-22	4	Satter Muneer A See footnote.	TKAI	Series D-2 Preferred Stock	C - Conversion	I			−457 728		0
2014-09-24	2014-09-22	4	Satter Muneer A See footnote.	TKAI	Series D-1 Preferred Stock	C - Conversion	I			−4 577 315		0
2014-09-24	2014-09-22	4	Satter Muneer A See footnote.	TKAI	Common Stock	P - Purchase	I		15,0000	150 000	2 250		1 771 688
2014-09-24	2014-09-22	4	Satter Muneer A See footnote.	TKAI	Common Stock	C - Conversion	I			1 621 688			1 621 688
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series E Preferred Stock	C - Conversion	I			−24 199 308		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series D-3 Preferred Stock	C - Conversion	I			−24 046 035		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series D-2 Preferred Stock	C - Conversion	I			−1 539 643		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series D-1 Preferred Stock	C - Conversion	I			−8 711 335		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series C Preferred Stock	C - Conversion	I			−14 604 833		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series B-2 Preferred Stock	C - Conversion	I			−644 786		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series B-1 Preferred Stock	C - Conversion	I			−798 067		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series A Preferred Stock	C - Conversion	I			−4 500 000		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Common Stock	P - Purchase	I		15,0000	362 500	5 438		7 912 079
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Common Stock	C - Conversion	I			7 549 570			7 549 579
2014-09-24	2014-09-22	4	Apple Tree Partners II - Annex, L.P.	TKAI	Series E Preferred Stock	C - Conversion	D			−24 199 308		0
2014-09-24	2014-09-22	4	Apple Tree Partners II - Annex, L.P.	TKAI	Series D-3 Preferred Stock	C - Conversion	D			−10 675 613		0
2014-09-24	2014-09-22	4	Apple Tree Partners II - Annex, L.P.	TKAI	Common Stock	P - Purchase	D		15,0000	237 500	3 562		3 568 438
2014-09-24	2014-09-22	4	Apple Tree Partners II - Annex, L.P.	TKAI	Common Stock	C - Conversion	D			3 330 938			3 330 938
2014-09-24	2014-09-22	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	A - Award	D	1,58		165 251		165 251
2014-09-24	2014-09-22	4	Novartis Bioventures Ltd	TKAI	Series E Preferred Stock	C - Conversion	D			−15 064 469		0
2014-09-24	2014-09-22	4	Novartis Bioventures Ltd	TKAI	Series D-3 Preferred Stock	C - Conversion	D			−13 222 826		0
2014-09-24	2014-09-22	4	Novartis Bioventures Ltd	TKAI	Series D-2 Preferred Stock	C - Conversion	D			−1 539 643		0
2014-09-24	2014-09-22	4	Novartis Bioventures Ltd	TKAI	Series D-1 Preferred Stock	C - Conversion	D			−15 396 431		0
2014-09-24	2014-09-22	4	Novartis Bioventures Ltd	TKAI	Common Stock	P - Purchase	D		15,0000	325 000	4 875		4 644 328
2014-09-24	2014-09-22	4	Novartis Bioventures Ltd	TKAI	Common Stock	C - Conversion	D			4 319 328			4 319 328
2014-09-24	2014-09-22	4	BARBERICH TIMOTHY J	TKAI	Series E Preferred Stock	C - Conversion	D			−809 955		0
2014-09-24	2014-09-22	4	BARBERICH TIMOTHY J	TKAI	Series D-3 Preferred Stock	C - Conversion	D			−457 731		0
2014-09-24	2014-09-22	4	BARBERICH TIMOTHY J	TKAI	Common Stock	C - Conversion	D			121 077			121 077
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series D-3 Preferred Stock	C - Conversion	D			−13 370 422		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series D-2 Preferred Stock	C - Conversion	D			−1 539 643		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series D-1 Preferred Stock	C - Conversion	D			−8 711 335		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series C Preferred Stock	C - Conversion	D			−14 604 833		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series B-2 Preferred Stock	C - Conversion	D			−644 786		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series B-1 Preferred Stock	C - Conversion	D			−798 067		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series A Preferred Stock	C - Conversion	D			−4 500 000		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Common Stock	C - Conversion	D			4 218 632			4 218 641
2014-09-24		3	Apple Tree Partners IV, L.P.	TKAI	Common Stock		D						250 000
2014-09-24		3	Apple Tree Partners IV, L.P.	TKAI	Common Stock		D						250 000
2014-09-18	2014-09-17	4	Kalowski Lee	TKAI	Stock Option (right to buy)	A - Award	D	15,00		218 417		218 417
2014-09-18	2014-09-17	4	Kalowski Lee	TKAI	Common Stock	A - Award	D			54 604			54 604
2014-09-16		3	Morrison Jodie Pope	TKAI	Common Stock		D						19 102
2014-09-16		3	Morrison Jodie Pope	TKAI	Common Stock		D						19 102
2014-09-16		3	APPLE TREE PARTNERS II LP	TKAI	Common Stock		D						18
2014-09-16		3	APPLE TREE PARTNERS II LP	TKAI	Common Stock		D						18
2014-09-16		3	Yanchik Joseph A., III	TKAI	Common Stock		D						51 092
2014-09-16		3	Yanchik Joseph A., III	TKAI	Common Stock		D						51 092
2014-09-16		3	Williams Martin D	TKAI	Common Stock		D						337 700
2014-09-16		3	Williams Martin D	TKAI	Common Stock		D						337 700
2014-09-16		3	Harrison Seth Loring See footnote.	TKAI	Common Stock		I						212 712
2014-09-16		3	Harrison Seth Loring	TKAI	Common Stock		D						425 397
2014-09-16		3	Harrison Seth Loring See footnote.	TKAI	Common Stock		I						212 712
2014-09-16		3	Harrison Seth Loring	TKAI	Common Stock		D						425 397

Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet

Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet

Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)

Omvandling av derivat

Försäljning eller överföring av värdepapper tillbaka til företaget

Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget

Överlåtelse av värdepapper från eller till insidern

Aktieswappar och liknande säkringsaffärer

Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)

En transaktion friviligt rapporterad på schema 4

Andra (med en fotnot som beskriver transaktionen)

ELDN / Eledon Pharmaceuticals, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5